Lawyers for Donald Trump on Wednesday said the US president has “absolute immunity” from a lawsuit by owners of the Cork Wine Bar in Washington, DC, who claim that his ownership of a nearby hotel constitutes unfair competition.
Trump’s lawyers, in seeking a dismissal of the lawsuit by Diane Gross and Khalid Pitts, said the president cannot be forced to close or divest the Trump International Hotel, located in the Old Post Office building on Pennsylvania Avenue, or else resign his office.
The doctrine of absolute immunity “ensures that the President can focus on carrying out the obligations of his Office without the distraction of virtually limitless litigation whose costs he would personally bear,” Trump’s lawyers said in a court filing. “That doctrine forecloses this lawsuit.”
Mark Zaid, a lawyer for the plaintiffs, disagreed.
“This lawsuit is against Donald J. Trump, not President Trump, and the cloak of immunity does not attach to his private, personal financial dealings,” Zaid said in an email.
The lawsuit is one of many targeting Trump’s alleged failure to distance himself from his business empire while in office.
Full Content: Law 360
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan